Ori-TTV particles enable potent in vivo CAR-T cell engineering for the treatment of hematologic malignancies and autoimmune diseases 2256860
Ori-TTV encodes a dual-target CAR recognizing both CD19 and BCMA, facilitating simultaneous elimination of malignant B and plasma cells and expands therapeutic potential across relapsed/refractory B-ALL, NHL, and MM, and B/plasma cell—driven autoimmune disorders such as systemic lupus erythematosus (SLE), idiopathic in...